Compare Ascendis Pharma A/S (ASND) vs Godaddy Inc (GDDY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Godaddy Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Godaddy Inc trades at $89.28 (market cap $11.77B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Godaddy Inc nearer its low. Which is the better fit depends on your goals.
| ASND | GDDY | |
|---|---|---|
Market Cap | $17.74B | $11.77B |
Sector | Health | Technology |
52-Week High | $277.18 | $169.79 |
52-Week Low | $163.32 | $75.07 |
Enterprise Value | $18.11B | $14.36B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
GoDaddy (GDDY) trades at $88.92, up 1.19% today, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 63.77% gross margin and 17.32% net margin, though revenue growth has slowed. Analyst consensus is bullish with a $123 price target, but legal investigations pose near-term sentiment risks.
Outlook remains positive based on fundamentals and analyst ratings, but investors should weigh the high ROE and cash flow strength against slowing revenue growth and ongoing legal scrutiny. The stock offers value at a P/E of 14.09, yet legal overhang may limit upside until resolved.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →
